The Prescription Drug User Fee Act (PDUFA), passed by the FDA in 1992 and renewed for the fifth time this year, aims to better utilize patient input to inform the drug research and approval process. Patients provide an essential perspective on the severity of a disease and insight into the implications that available treatments (or lack thereof) have on their condition. Within the PDUFA, the Patient-Focused Drug Development initiative plans to explore 20 disease areas by featuring each one in an FDA public meeting.
Uncategorized
Voice Your Opinion Now: FDA to Consider 20 Disease Areas at Public Meetings
